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ABSTRACT
The PI-3 kinase (PI-3K)/mTOR pathway is critical for cell growth and 
proliferation. Strategies of antagonising this signaling have proven to be detrimental 
to cell survival. This observation, coupled with the fact many tumours show enhanced 
growth signaling, has caused dual inhibitors of PI-3K and mTOR to be implicated 
in cancer treatment, and have thus been studied across various tumour models. 
Since PI-3K (class-I)/mTOR pathway negatively regulates autophagy, dual inhibitors 
of PI-3K/mTOR are currently believed to be autophagy activators. However, our 
present data show that the dual PI-3K/mTOR inhibition (DKI) potently suppresses 
autophagic flux. We further confirm that inhibition of Vps34/PI3KC3, the class-III 
PI-3K, causes the blockade to autophagosome-lysosome fusion. Our data suggest 
that DKI induces cell death independently of apoptosis and necroptosis, whereas 
autophagy perturbation by DKI may contribute to cell death. Given that autophagy is 
critical in cellular homeostasis, our study not only clarifies the role of a dual PI-3K/
mTOR inhibitor in autophagy, but also suggests that its autophagy inhibition needs 
to be considered if such an agent is used in cancer chemotherapy.
INTRODUCTION
Macroautophagy (autophagy hereafter), is a bulk 
degradation system that mediates clearance of unwanted 
cytoplasmic constituents, including aberrant long-lived 
cytoplasmic proteins, intracellular pathogens and damaged 
organelles such as mitochondria [1-3]. Autophagy involves 
the formation of double-membrane structures called 
autophagosomes which engulf portions of cytoplasm. 
They are then trafficked to lysosomes where their contents 
are degraded after fusion [1]. During autophagosome-
lysosome fusion, autophagosomes may directly fuse 
with lysosomes, or initially fuse with late endosomes to 
form amphisomes, which then subsequently fuse with 
lysosomes [4].
The ULK1/2-Atg13-FIP200 complex senses the 
signals for autophagosome initiation and stimulates the 
downstream class-III PI-3 kinase (PI-3K), Vps34 [5, 
6]. Beclin 1-Vps34 complex generates PtdIns3P (PI(3)
P), which is required for autophagosome/phagophore 
nucleation [7]. Autophagosome elongation involves 
two essential ubiquitin-like (UBL) conjugations: 
the conjugation of the UBL protein Atg12 to Atg5, 
and the conjugation of the UBL protein LC3 to 
phosphatidylethanolamine (PE). Atg5-Atg12 conjugation 
is catalysed sequentially by E1-like enzyme Atg7 and E2-
like enzyme Atg10 [8]. The Atg5-12 conjugate (Atg5-12) 
is an E3 ligase to catalyse LC3-PE (LC3-II) conjugation 
that also requires E1-like Atg7 and E2-like Atg3 [9-
11]. LC3-II, the lipidated form of LC3, is required for 
the expansion and completion of pre-autophagosomal 
membranes [12-14]. 
The ligation of growth factors to their receptors 
activates the class-I PI-3K and AKT kinase, that in 
turn activate mammalian target of rapamycin (mTOR) 
by inhibition of mTOR negative regulator TSC2, thus 
stimulating cell growth and proliferation [15]. mTOR 
has a number of downstream biological effects, including 
protein translation via phosphorylation of 4E-BP1 and p70 
S6 kinase [16]. Under nutrient replete conditions, the TOR 
kinase negatively regulates autophagosome formation 
[17] via phosphorylation of Atg13 and ULK1, the 
upstream signals of autophagy initiation [18]. Autophagy 
is activated by starvation via multiple signals, including 
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mTOR inhibition, and AMP-activated protein kinase 
activation [19].
The PI-3K/mTOR pathway is over-activated in 
many cancer cells [20, 21]. Therefore, it is crucial to target 
this pathway to suppress growth and induce cell death in 
these cells for therapeutic purpose. Chemical compounds 
targeting both PI-3K and mTOR, such as PI-103 and NVP-
BEZ-235, have been designed to better target the survival 
signaling pathway [22, 23]. These compounds have shown 
potent effects in inhibiting cell survival and promoting 
cell death [24, 25], as well as enhancing the efficacy of 
chemotherapy and radiotherapy when used in combination 
treatments [26, 27]. Currently, PI-103 has been tested 
for treating many cancer models, such as gliomas 
[25, 28], AML leukemia [29] and prostate and breast 
carcinomas [30], amongst others. NVP-BEZ-235 has been 
investigated in a number of clinical trials as a potential 
chemotherapeutic for solid tumours seen in breast cancer 
(ClinicalTrials.gov ID: NCT01495247) and renal cell 
carcinoma patients (NCT01453595), as well as castration-
resistant forms of prostate cancer (NCT01717898) and 
pancreatic neuroendocrine tumours (NCT01628913). Such 
dual kinase inhibitors will be further exploited for cancer 
therapy, with new agents entering clinical trials [31]. 
Dual inhibitors of PI-3K/mTOR are currently 
viewed as autophagy activators [28, 32, 33] since they 
simultaneously inhibit class-I PI-3K and mTOR [25], 
both of which suppress autophagy. However, this notion 
may be an oversimplification, as different classes of PI-
3Ks have opposing effects on autophagy [34]. Whilst the 
class-I PI-3K does indeed inhibit autophagy initiation [35], 
the class-III PI-3K (Vps34 in mammals) generates PI(3)
P for autophagosome nucleation and promotes autophagy 
[4]. We unexpectedly found that rather than inducing 
autophagy, dual PI-3K/mTOR inhibition (DKI) strongly 
inhibits the later stage of autophagy. This effect appears 
to be the result of inhibition of the class-III PI-3K Vps34, 
which causes a defect to autophagosome maturation. Our 
present data suggest that autophagy inhibition by the dual 
inhibitors may contribute to their toxicity, thereby offering 
a mechanism of cell death induction by dual inhibitors of 
PI-3K/mTOR.
RESULTS
Dual inhibition of PI-3K/mTOR causes an 
increase in autophagosome numbers
As PI-3K/Akt/mTOR negatively regulates 
autophagy, DKI has been suggested to stimulate 
autophagy [28, 32, 33]. We first tested this by quantifying 
the numbers of GFP-LC3 positive vesicles exploiting DKI 
drug PI-103 treatment. The number of GFP-LC3 vesicles 
was markedly increased after PI-103 treatment in GFP-
LC3 stably expressing HeLa cells, as reported previously 
[28], to an extent similar to the lysosomal degradation 
inhibitor Chloroquine (CQ) (Figure 1A). We observed the 
same effect in RT4-D6P2T neuronal Schwann (RT4) cells 
(Supplementary Figure 1). Autophagosome-associated 
protein LC3-II has been used as an autophagosome marker 
since the levels of LC3-II correlate with autophagosome 
numbers [1]. Likewise, PI-103 robustly increased LC3-II 
levels in these cells as detected by immunoblot. Of note, 
the effect was only slightly enhanced by the lysosomal 
inhibitor Bafilomycin A1 (Baf), but markedly reduced 
by the PI-3K inhibitor 3-methyladenine (3-MA), and 
phosphorylation of p70S6 kinase (p70S6K) (threonine 
389), a prominent mTOR substrate, was inhibited by PI-
103, confirming that PI-103 strongly inhibited mTOR 
kinase activity in our system (Figure 1B). We further 
assessed the effects of the drug treatment on a number 
of mTOR/PI-3K substrates (Figure 1C). Similarly, the 
phosphorylation of AKT (Serine 473) by PI-3 kinase and 
mTOR [36, 37], and that of ULK1 (Serine 757) by mTOR 
[18], were also decreased by PI-103 (Figure 1C). Of note, 
rapamycin treatment does not appear to significantly block 
the phosphorylation of ULK1 in our conditions. It was 
revealed that rapamycin inhibits S757 phosphorylation 
of ULK1 in short-term treatment (1 hour) condition [18]. 
This suggests that longer-term rapamycin treatment (20 
hours) in our conditions may exert additional or feedback 
effect, leading to reduction in S757 phosphorylation of 
ULK1. Together, these data suggest that PI-103 induces 
the initiation of autophagosome formation, given that the 
phosphorylation of AKT and ULK1 blocks autophagosome 
synthesis [18, 36]. Indeed, PI-103 treatment led to an 
elevation in Atg5-12 puncta, as detected by Atg12 staining 
(Figure 1D). 
Since autophagy encompasses the delivery of 
LC3-II-associated autophagosomes to lysosomes and 
their subsequent breakdown (‘autophagy flux’) [1, 38], 
increases in LC3-II can also be indicative of a blockade 
to autophagosome degradation. To test if PI-103 altered 
autophagy flux, we utilized Baf, that blocks lysosomal 
acidification and prevents subsequent autophagosome 
clearance [39]. Figure 1E shows that PI-103 massively 
increased the level of LC3-II (LC3B-II) (~10 fold) in 
HeLa cells. However, this increase (~2 fold) was largely 
weakened in the presence of Baf, suggesting that PI-103 
may also inhibit lysosomal function or autolysosome 
formation. In accordance with this, qPCR analysis revealed 
that PI-103 treatment caused no significant alterations to 
LC3-B mRNA levels (Figure 1F). This indicates the drug-
induced LC3-II increases are likely at the protein level, so 
potentially the result of impaired degradation. 
PI-103 blocks autophagic flux
Our data unexpectedly suggested that DKI may 
impair autophagy. To explore this possibility further, we 
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used additional methods of assessing autophagy flux. 
p62 recruits cargo to be engulfed by autophagosomes 
and is subsequently degraded by lysosomal enzymes 
after autophagosome-lysosome fusion [40]. As p62 is 
an autophagy substrate, increased autophagy levels are 
associated with p62 clearance. Consistently, we found 
that after PI-103 treatment, the clearance of p62 was 
impaired in HeLa cells (Figure 2A) and either wild-
type (WT) or Bax/Bak double knockout (DKO) mouse 
embryonic fibroblasts (MEFs) [41, 42] (Figure 2B). The 
PI-103-induced decrease in p62 clearance was maintained 
at both 24 and 48 hours post drug treatment (Figure 
Figure 1: PI-103 causes autophagosome accumulation. A. GFP-LC3 was transfected into HeLa cells. After 16 hours, cells were 
treated with vehicle (DMSO), PI-103 (PI) (5uM) or CQ (25uM). The cells were analysed after a further 20 hours. The numbers of GFP-LC3 
vesicles representing autophagosomes are assessed (n = 30 cells per condition). Data are shown as mean ±sd. ***: P < 0.001. Scale bar: 
20um. B. HeLa cells were treated with vehicle, PI (1uM), PI (1uM)+Baf (100nM), or PI (1uM)+ 3-MA (10mM) for 20 hours. Blots were 
probed with the indicated antibodies. C. HeLa cells were treated with vehicle, rapamycin (Rap) 2uM, LY294002 (LY) (10uM), and PI as 
shown for 20 hours, then analysed by immunoblot with the indicated antibodies. D. HeLa cells were treated with vehicle, PI (1uM) or/and 
CQ (25uM) for 20 hours, then fixed and stained with Atg12 antibody. Images were taken by confocal microscopy. The number of Atg12 
puncta per cell were counted (n = 30 cells per condition). Data are presented as mean ±sd. Scale bar: 10um. E. HeLa cells were treated with 
vehicle, PI (5uM) for 20 hours with or without Baf (400nM) for 4 hours. Blots were probed with the indicated antibodies. Quantification 
is shown as mean LC3-II/tubulin. **: P < 0.01. F. HeLa cells were treated with vehicle or PI (5uM) for 20 hours. Isolated RNA was then 
analysed by qRT-PCR to detect LC3-B mRNA expression (experiments were performed in triplicate, with n = 3 per experiment). Data are 
shown as mean ±sd of relative mRNA levels (normalised to actin). NS: not significant.
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2C). Similarly, the numbers of cytoplasmic p62 puncta 
observable by immunocytochemistry were elevated 
by PI-103, but not significantly enhanced when used 
in combination with CQ (Figure 2D). Additionally, no 
significant alterations to p62 mRNA levels were detectable 
during PI-103 treatment, indicating these increases 
occur at the protein level (Figure 2E). Taken together, 
these findings suggest that autophagy flux is inhibited 
by PI-103. We aimed to verify this using an alternative 
autophagy substrate. The Huntington’s Disease protein, 
mutant huntingtin with expanded polyQ (mHtt), is known 
to form protein aggregates that are subject to autophagic 
Figure 2: PI-103 blocks autophagic flux. A. HeLa cells were treated with PI-103 (PI) as indicated with or without CQ (25uM) for 
20 hours. Blots were probed with the indicated antibodies. B. WT and Bax/Bak DKO MEFs were treated with PI as indicated for 20 hours 
and subjected to immunoblot with the antibodies shown. C. HeLa cells were treated with vehicle and PI (1uM) at the indicated times and 
analysed by immunoblotting. D. HeLa cells were treated with vehicle, PI (1uM), CQ (25uM) or PI (1uM)+CQ (25uM) as indicated for 20 
hours. Cells were fixed and stained for p62, and images taken by confocal microscopy. The numbers of p62 puncta per cell were counted 
(n = 30 cells per condition). Data are shown as mean ±sd. ***: P < 0.001. Scale bar: 10um. E. HeLa cells were treated with vehicle or PI 
(5uM) for 20 hours. RNA was isolated and analysed by qRT-PCR to detect p62 expression (experiments were performed in triplicate, with 
n = 3 per experiment). Data are shown as mean ±sd of relative mRNA levels (normalised to actin). NS: not significant. F. HeLa cells were 
transfected with GFP-Huntingtin (Htt)-72Q and treated with vehicle, PI (0.5 and 1uM) or CQ (25uM) 24 hours post transfection. Cells 
were fixed after a further 4 days, and the number of Htt aggregates-positive cells per 300 cells was recorded. Data are presented as mean 
±sd. *: P < 0.05. 
Oncotarget5161www.impactjournals.com/oncotarget
clearance, and therefore can be used as another indicator 
of autophagy flux [43, 44]. We observed an increase in the 
number of mHtt aggregates after PI-103 addition, to an 
extent comparable to CQ (Figure 2F), providing further 
support for a role of DKI in inhibition of autophagy. 
PI-103 blocks autophagosome-lysosome fusion
As the DKI drug PI-103 appeared to disrupt 
autophagy flux, we next sought to investigate whether 
this effect was the result of changes to lysosome acidity 
or integrity. Acridine orange (AO) is a lysosomotropic 
metachromatic fluorochrome that emits red fluorescence 
under acidic pH, which is normally in late endosomes/
lysosomes, and green fluorescence otherwise [45]. Thus, 
reduced red fluorescence may reflect the reduced integrity 
of lysosome membranes. To further characterise the effect 
of PI-103 on lysosomal mass or membrane integrity, AO 
was used to stain lysosomes in RT4 cells treated with PI-
103. In Figure 3A, we consistently observed that PI-103 
induced lysosomal accumulation, but did not compromise 
lysosomal membrane integrity, whereas Baf treatment, 
which results in a defect in lysosomal acidification [39], 
was associated with a markedly reduced signal (Figure 
3A). Similar observations were made with an alternative 
pH sensitive dye, LysoSensor Green. Whilst Baf caused 
a notable reduction in acidic vesicles, lysosomes 
were retained with PI-103 treatment (Figure 3B). Cell 
fractionation experiments confirmed that PI-103 did not 
compromise the integrity of lysosome membranes, since 
the pool of lysosomal cathepsin D was not reduced in PI-
103-treated cells, compared to the control cells (Figure 
3C). Although the acidity and integrity of lysosomes 
appeared to remain intact during PI-103 treatment, we 
noted a degree of vesicle accumulation with AO (Figure 
3A). We confirmed the lysosome accumulation effect using 
the lysosomal membrane protein LAMP1, with a stronger 
signal seen in PI-103-treated cells compared to that in 
control cells (Figure 3D). Following this, we explored if 
autophagosome-lysosome fusion was impaired. To do this, 
we employed mRFP-GFP-LC3 stably expressing cells to 
monitor autophagosome synthesis and autophagosome-
lysosome fusion, as autophagosomes appear yellow (with 
green and red) and autolysosomes as red vesicles, since 
the low lysosomal pH quenches GFP more quickly than 
mRFP [46]. Following PI-103 treatment, the number 
of autophagosomes increased, whilst autolysosomes 
markedly decreased (Figure 3E), indicating a blockade 
to autophagosome-lysosome fusion/autophagosome 
maturation. The decrease in autophagosome-lysosome 
fusion was comparable to that following Baf treatment 
(Figure 3E). Therefore, these findings suggest PI-103 
perturbs autophagy flux.
NVP-BEZ-235 also inhibits autophagy flux
Our data indicated that PI-103 inhibits autophagy 
flux. To assess the consistency of this DKI-induced 
defect on autophagic flux, we further examined another 
prominent PI-3K/mTOR dual inhibitor, NVP-BEZ-235 
(BEZ-235). Treatment with BEZ-235 increased LC3-II 
levels (Figure 4A). Similarly, BEZ-235 did not further 
increase LC3-II levels in the presence of Baf (Figure 4A), 
suggesting that BEZ-235 blocks autophagosome-lysosome 
fusion, rather than solely increase autophagosome 
biogenesis. BEZ-235 also prevented autophagic substrate 
p62 degradation (Figure 4B), lending further support to 
BEZ-235 inhibiting autophagic flux. 
To further test whether DKI impairs autophagosome-
lysosome fusion and subsequently causes autophagosome 
accumulation, we again utilized mRFP-GFP-LC3 stably 
expressing cells for BEZ-235 treatment. As with PI-103, 
BEZ-235 treatment caused autophagosome number to 
largely increase, while autolysosome number dramatically 
decreased, indicating autophagosome-lysosome fusion 
was blocked (Figure 4C). The changes were comparable 
to those resulting from the lysosome inhibitor Baf (Figure 
4C). Therefore, DKI actually blocks rather than activates 
autophagic flux, although autophagosome accumulation 
was observed.
Vps34 is required for autophagosome-lysosome 
fusion
As the lysosomal effects of DKI had not been 
previously reported, we were interested in determining 
the mechanism by which these effects were mediated. To 
dissect DKI-targeted autophagy pathways, we employed 
a pharmacological strategy by using the single treatments 
of mTOR inhibitor rapamycin (Rap), and PI-3K inhibitor 
LY294002 (LY), or the combinatory treatment of Rap+LY. 
Both Rap and LY are widely used in autophagy research, 
with Rap inducing autophagosome synthesis [47], and 
LY inhibiting this process [48]. We first applied the 
treatment strategy to mRFP-GFP-LC3 cells. Whilst Rap 
incubation caused a significant increase in autolysosomes, 
indicating an increased autophagy flux, LY treatment 
caused a decline in these vesicles. The reduction of 
autolysosomes was similar between LY and Rap+LY 
combination treatments (Figure 5A). However, the 
Rap+LY combination treatment enhanced autophagosome 
numbers (Figure 5A). These data suggested that whilst 
loss of mTOR with DKI leads to elevated autophagosome 
synthesis, PI-3K ablation may result in the blockade to 
autophagosome maturation and subsequent degradation. 
Consistently, Rap caused an increase in the levels of LC3-
II whereas LY led to a decrease (Figure 5B). However, the 
combination of both agents resulted in a further increase 
in LC3-II levels compared to Rap alone, to a magnitude 
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Figure 3: PI-103 blocks autophagosome-lysosome fusion. A. RT4 cells were treated with vehicle, PI (1uM) or Baf (100nM) for 
16 hours and then stained with acridine orange (AO) for 15 mins. Representative live cell images were taken on a confocal microscope. 
Scale bar: 5um. B. HeLa cells were treated with vehicle and PI (1uM) for 16 hours, or Baf (400nM) for 4 hours, and then stained with 1uM 
LysoSensor Green DND-189 for 30 minutes. Representative live cell images were taken on a confocal microscope. Scale bar: 10um. C. 
HeLa cells were treated with vehicle or PI (1uM) for 24 hours and fractionated to separate cytosolic and membrane components. Lysates 
were then subjected to SDS-PAGE and probed with the indicated antibodies. D. HeLa cells were treated with vehicle, PI-103 (PI) (1uM) 
or Baf (100nM) for 24 hours, then fixed and stained for LAMP1. Representative images were taken on a confocal microscope. Scale bar: 
10um. E. mRFP-GFP-LC3 stably expressing HeLa cells were treated with vehicle , PI (1uM), Baf (100nM) or PI (1uM)+Baf (100nM) for 
20 hours. Cells were then fixed and confocal images were acquired. The numbers of autophagosomes (green vesicles) and autolysosomes 
(red vesicles minus green vesicles) were assessed with automated Cellomics microscopy (n = 12). Data are shown as mean ±sd. ***: P < 
0.001. Scale bar: 20um. 
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similar to PI-103 (Figure 5B). This suggests that PI-3K 
inhibition is critical in the suppression of autophagy 
flux. We postulated that the effect of PI-3K inhibition on 
autophagosome maturation is attributable to loss of PI(3)
P, since PI(3)P is a product of the Class III PI-3K [49] and 
has been associated with roles in autophagosome synthesis 
[7], as well as vesicle trafficking, endosome maturation 
and autophagosome maturation [50-53]. GFP-2xFYVE 
has been used as a bona fide probe to detect intracellular 
PI(3)P levels [54], thus we assessed the effects of drugs 
on PI(3)P levels in cells expressing GFP-2xFYVE. As 
expected, FYVE puncta were increased with rapamycin. 
However, PI-3K inhibition, with either LY or PI-103, 
caused a reduction in both number and size of FYVE dots, 
with more diffuse FYVE signal (Figure 5C). With PI-3K 
pharmacological inhibition and the subsequent reduction 
in PI(3)P seemingly disrupting autophagy flux, we aimed 
to fortify this observation with a more specific genetic 
approach by knocking down mTOR, Vps34 (kinase 
subunit of class III-PI-3K complex) or both mTOR and 
Figure 4: The effect of NVP-BEZ-235 on autophagy. A. HeLa were treated with vehicle, NVP-BEZ-235 (BEZ-235) (0.5uM) for 20 
hours with or without Baf (400nM) for 4 hours. Cell lysates were subjected to immunoblotting with the indicated antibodies. B. HeLa cells 
were treated with BEZ-235 at indicated concentrations, with or without CQ (25uM) for 20 hours. The lysates were analysed by immunoblot. 
C. mRFP-GFP-LC3 stably expressing HeLa cells were treated with vehicle or BEZ-235 (0.5uM) for 20 hours, and Baf (400nM) for 4 
hours. Cells were then fixed and confocal images were acquired. The numbers of autophagosomes (green vesicles) and autolysosomes (red 
vesicles minus green vesicles) were assessed (n = 30 cells per condition). Data are shown as mean ±sd. ***: P < 0.001. Scale bar: 10um.
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Figure 5: Inhibition of Class III PI-3K decreases autophagosome-lysosome fusion. A. mRFP-GFP-LC3 stably expressing 
HeLa cells were treated with vehicle, rapamycin (Rap) (2uM), LY294002 (LY) (10uM), Rap (2uM)+LY (10uM) for 24 hours and the 
numbers of autophagosomes and autolysosomes were counted. Data are shown as mean ±sd (n = 30 cells per condition). ***: P < 0.001. 
Scale bar = 10um. B. HeLa cells were treated with Rap and LY as in A and PI-103 (PI) (1uM) for 24 hours and analysed by immunoblot with 
the indicated antibodies. C. HeLa cells were transfected with GFP-2xFYVE. 24 hours after transfection, cells were treated as in B and then 
fixed after a further 24 hours. Images were taken by confocal microscopy. The number of GFP-2xFYVE puncta per cell were counted (n = 
30 cells per condition). Data are shown as mean ±sem. Scale bar: 10um. D. mRFP-GFP-LC3 stably expressing HeLa cells were transfected 
with control, mTOR and Vps34 siRNA as indicated for 48 hours (i). Autophagosomes (green vesicles) and autolysosomes (red vesicles 
minus green vesicles) were counted (n = 30 cells per condition) (ii ). All counts are shown as mean ±sd. Scale bar = 10um. Knockdown 
efficiency was confirmed with immunoblot. E. HeLa cells were transfected with control or Vps34 siRNA. 24 hours post transfection, cells 
were treated with vehicle, Baf (100nM) and CQ (25uM) for a further 20 hours, then analysed by immunoblot with the indicated antibodies. 
F. Control or Vps34 siRNA was co-transfected with GFP-2xFYVE for 48 hours. Cells were fixed and FYVE vesicles were quantified (n = 
30). Data are shown as mean ±sd. Scale bar: 10um. 
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Vps34, and assessing autophagosome maturation in 
mRFP-GFP-LC3 cells. As expected, mTOR knockdown 
caused increases in the numbers of autophagosomes and 
autolysosomes (Figure 5D), which are plausibly the result 
of increased autophagosome synthesis and maturation 
caused by decreased mTOR activity. Interestingly, Vps34 
knockdown increased LC3-positive vesicles (Figure 
5D), unlike LY treatment (Figure 5A), presumably 
because LY does not solely inhibit Vps34 activity, but 
targets broader PI-3Ks. Vps34 knockdown appeared to 
block autophagosome maturation as autophagosome-
lysosome fusion was compromised in Vps34 knockdown 
cells (Figure 5D). Both mTOR and Vps34 knockdown 
caused a further increase in autophagosome numbers 
(Figure 5D). Immunoblot analysis also confirmed that 
Vps34 knockdown increased LC3-II levels (Figure 5E). 
Notably, the effect was lost when cells were treated with 
the lysosomal inhibitors Baf or CQ (Figure 5E), indicating 
that Vps34-induced LC3-II accumulation is the result 
of impairment to autophagosome degradation, rather 
than enhanced autophagosome synthesis. These data, in 
agreement with those recently reported [55], confirm that 
LC3 lipidation is independent of Vps34 activity. Jaber et al 
[55] also reported that LC3 protein self-aggregation may 
partially account for LC3-positive vesicle accumulation in 
Vps34-null cells. Interestingly, a highly selective Vps34 
inhibitor, PIK-III, also strongly induces accumulation 
of LC3-II/autophagosomes [56]. Although Vps34 is 
critical in PI(3)P generation, as we confirmed in Figure 
5F, for autophagosome formation [7], it has been 
suggested to be dispensable for the process [57-59], but 
required for autophagosome maturation since Vps34 is 
critical in endosomal/lysosomal trafficking [53, 55] (see 
Discussion for more details). The knockdown efficiency 
of Vps34 and mTOR was also confirmed by qPCR 
(Supplementary Figure 2), in addition to immunoblot 
(Figure 5D). Our data, consistent with these previous 
findings, reveal that Vps34 inhibition by DKI results in 
defective autophagosome-lysosomal fusion, suggesting a 
mechanism by which DKI exerts an inhibitory effect on 
autophagy. 
Figure 6: PI-103 treatment induces cell death and inhibits cell proliferation. A. RT4 cells were treated with vehicle, PI (0.1 
uM) or Bafilomycin A1 (Baf, 10 nM). Cell viability was measured via ATP assay kit (Promega) (n = 6). Data are shown as mean ±sd ***: 
P < 0.001. B. RT4 cells were treated with vehicle or PI (0.5uM) (24 hours) and cell death was measured using propidium iodide staining 
in flow cytometry (n= 3 per treatment). Data are shown as mean ±sd. **: P < 0.01. C. HeLa cells were treated with vehicle (as a negative 
control), PI (5uM) or staurosporine (STS) (1uM) (as a positive control) for the times indicated. Cell proliferation was measured by BrdU 
assay (i) and viability by MTT assay (ii). Viability readings were then corrected by subtracting results from the BrdU assay (iii) (n = 6 per 
condition). Data are shown as mean ±sd. 
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DKI treatment induces cell death and inhibits 
cells proliferation
DKI treatments are known to be able to induce 
cell death, hence are attractive for tumour therapy [25, 
26, 28, 31, 33]. We found the viability of RT4 cells to be 
sensitive to PI-103 treatment (Figure 6A, Supplementary 
Figure 3), thus used the cells for further cell death assays. 
The cells also showed a significant increase in cell death 
with the drug (Figure 6B). As the difference between 
the viability loss and cell death extent was notable, we 
reasoned this could be the result of additional factors that 
are encompassed by cell viability measurements, such as 
growth and proliferation, because both cell growth and 
proliferation are positively regulated by the PI-3K/mTOR 
pathway [15]. We confirmed this in HeLa cells treated with 
PI-103 by simultaneously comparing cell proliferation and 
viability. Over the time course, a decline in both measures 
was seen (Figure 6C (i-ii)), and the cell death shown by 
correcting viability for proliferation was still observable 
(Figure 6C (iii)). Thus, DKI treatments induce cell death, 
and also suppress cell proliferation. 
Cell death induced by DKI is independent of 
apoptosis
Previous studies, based on the fact that DKI 
induces production of apoptosis markers, suggested that 
DKI drug treatments execute cell death via the caspase-
mediated apoptosis pathway [28, 60]. However, it was not 
clear if inhibition of apoptosis suppresses DKI-induced 
cell death. In order to further test this, we applied the 
pan-caspase inhibitor zVAD-fmk (zVAD) to PI-103 
treatments. Unexpectedly, zVAD afforded no protection 
from PI-103 mediated cytotoxicity, suggesting that this 
effect was independent of apoptosis (Figure 7A). This 
phenomenon was not altered by extending the timeframe 
of the treatment to 48 hours (Figure 7B, Supplementary 
Figure 4). As apoptosis is mediated by caspase cleavage 
and activation, we explored caspase-3 cleavage in 
response to PI-103. Cleaved caspase-3 was not detectable 
in the cells treated with PI-103 for 20 hours, in contrast 
to the apoptosis inducing combination treatment of 
TNF and cycloheximide (CHX) (Figure 7C). Likewise, 
genetic knockdown of caspase-3 afforded no cell death 
protection to HeLa cells from PI-103 treatment, unlike that 
provided by the pan caspase inhibitor zVAD to TNF+CHX 
treatment (Figure 7D). To fortify this observation, we also 
assessed the effect of knocking down caspase-8 (Figure 
7E) and caspase-9 (Figure 7F) on PI-103 induced cell 
death, and consistently saw no alleviation to the toxicity. 
Interestingly, it is noted that caspase-9 knockdown 
consistently caused more rather than less cell death in 
the cells treated with PI-103 (Figure 7F). Caspase-9 was 
suggested to regulate autophagy activity, and its inhibition 
blocks autophagy through modulating lysosomal pH and 
acidic-dependent cathepsin activity, thus augumenting 
cell death [61]. Finally, we investigated differences in 
viability between WT and apoptosis defective Bax/Bak 
DKO MEFs with PI-103 treatment, and compared these 
results with staurosporine (STS), an agent known to kill 
cells via apoptosis [62]. Whilst the loss in viability with 
STS was largely rescued in the DKO MEFs, the effect was 
much more marginal with PI-103, indicating a relatively 
minor role for apoptosis in the activity of this drug (Figure 
7G). Together, these results suggest that apoptosis is not a 
major contributor to the viability loss and death associated 
with DKI treatments. 
DKI-induced cell death is independent of 
necroptosis
 As apoptosis did not appear to be a major effector 
of PI-103 cytotoxicity, we next explored the involvement 
of another programmed cell death pathway, necroptosis. 
A key positive regulator of this process is RIP1, meaning 
that inhibition of this protein also prevents necroptosis 
onset [63, 64]. We first assessed the effect of the widely 
used necroptosis inhibitor Necrostatin-1 (Nec) [63, 65] on 
PI-103 cytotoxicity. As with apoptosis, loss of necroptosis 
provided no rescue of cell viability with PI-103 treatment 
(Figure 8A). Similarly, genetic knockdown of RIP1 did 
not afford protection from cell death in the cells treated 
with PI-103 (Figure 8B). Finally, we compared the effects 
of Nec on cell death with PI-103 or the artemisinin-
based drug artesunate (ART), which we have previously 
demonstrated to induce necroptosis in RT4 cells [66]. 
Whilst ART toxicity was largely attenuated by the addition 
of Nec, no such effect occurred with PI-103 treatment 
(Figure 8C). Taken together, these results indicate that 
DKI induced cell death is independent of necroptosis.
As neither apoptosis nor necroptosis suppression 
significantly alleviated DKI-induced cell death, we 
reasoned that it was possible one pathway could 
compensate for the other. However, synergistic use of 
zVAD and Nec had no effect on cell death (Figure 8D) or 
viability loss (Figure 8E) with PI-103 treatment. Based on 
this, we ventured that alterations to autophagy from the 
drug treatment may have a role. Indeed, over a series of 
PI-103 concentrations the extent of cell death correlated 
with the numbers of autophagosomes in cells (Figure 
8F). Autophagy is involved in a number of intracellular 
pro-survival roles, such as toxin clearance and resistance 
against various stresses. Therefore, while appreciating that 
it is unlikely that DKI-induced cell death is only attributed 
to a single pathway, we reason that autophagy dysfunction 
may contribute to the cell death.
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Figure 7: PI-103 induces cell death independent of apoptosis. A. RT4 cells were treated with a series of concentrations of PI-103 
(PI) alone, or with pan-caspase inhibitor zVAD-fmk (zVAD) (20uM) for 24 hours. Cell viability was measured via ATP assay kit (Promega) 
(n = 6 per condition). Data are shown as mean ±sd (note that the error bars are not visible due to minor variations). B. RT4 cells were 
treated with PI (0.5uM) with or without zVAD (20uM) for the time periods indicated, and cell viability was measured via MTT assay (n = 
6 per condition). Data are shown as mean ±sd. C. HeLa cells were treated with vehicle, PI (5uM) or TNF (30ng/ml)+cycloheximide (CHX, 
30uM) (as a positive control) for 20 hours and analysed by immunoblot with the indicated antibodies. D. HeLa cells were transfected with 
control or caspase-3 siRNA for 24 hours then treated with vehicle or PI (5uM) for 48 hours. Cell death was measured with propidium iodide 
staining (n = 6 per condition). TNF+CHX±zVAD was used as additional controls for apoptosis inhibition. Data are shown as mean ±sd. 
***: P < 0.001, *: P < 0.05. Immunoblot was used to verify knockdown efficiency. E. HeLa cells were transfected with control or caspase-8 
siRNA for 24 hours then treated with vehicle or PI (5uM) for 20 hours. Cell death was measured with propidium iodide staining (n = 6 per 
condition). Data are shown as mean ±sd. **: P < 0.01. Immunoblot was used to verify knockdown efficiency. F. HeLa cells were transfected 
with control or caspase-9 siRNA for 24 hours then treated with vehicle or PI (5uM) for 48 hours. Cell death was measured with propidium 
iodide staining (n = 6 per condition). Data are shown as mean ±sd. Immunoblot was used to verify knockdown efficiency. G. WT MEF 
or Bax/Bak DKO MEFs were treated with vehicle, PI (3uM), or STS (1uM) for 24 hours. Cell viability was measured via ATP assay kit 
(Promega) (n = 12 per condition). Data are shown as mean ±sd. 
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Figure 8: PI-103 induces cell death independent of necroptosis. A. RT4 cells were treated with a series of concentrations of 
PI-103 (PI) alone, or with necroptosis inhibitor necrostatin-1 (Nec) (20uM) for 24 hours. Cell viability was measured via ATP assay kit 
(Promega) (n = 6 per condition). Data are shown as mean±sd (note that the error bars are not visible due to minor variations). B. HeLa 
cells were transfected with control and RIP1 siRNA for 24 hours then treated with vehicle or PI (5uM) for 20 hours. Cell death was 
measured with propidium iodide staining (n = 6 per condition). Data are shown as mean ±sd. *: P < 0.05. Immunoblot was used to verify 
knockdown efficiency. C. RT4 cells were treated with vehicle, PI (1uM), or artemisinin analogue, artesunate (ART) (25uM) with or 
without Nec (20uM) for 24 hours. Cell death was measured with propidium iodide staining (n = 6 per condition). ART (25uM) or/and Nec 
were used as additional controls for necroptosis inhibition. Data are shown as mean ±sd. **: P < 0.01. D. HeLa cells were treated with PI 
(5uM), zVAD (20uM) and Nec (20uM) for 24 hours. Cell death was measured with propidium iodide staining (n = 3 per condition). Data 
are shown as mean ±sd. E. RT4 cells were treated with vehicle, PI-103 (PI) (0.5uM), z-VAD (20uM) and nec (20uM) as indicated for 24 
hours. Cell viability was measured with MTT assay (n = 6 per condition). Data are shown as mean ±sd. ***: P < 0.001. F. RT4 cells were 
treated with concentrations of PI as indicated (24 hours). Cell viability was assessed with ATP assay kit (Promega) (n = 6 per condition)). 
Autophagosome (Apg) numbers were assessed in matching RT4 cells with GFP-LC3 by automated Cellomics microcopy (n = 12 per 
condition). Data are shown as mean ±sd.
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DISCUSSION
In this study, we show that two dual inhibitors of 
mTOR and PI-3K, PI-103 and NVP-BEZ-235, inhibit 
autophagy, suggesting that this effect is common across all 
such agents. Interestingly, our data also strongly suggest 
DKI-induced cell death is independent of apoptosis and 
necroptosis, and inhibition of autophagic flux by DKI may 
contribute to its-induced cell death.
DKI appears to inhibit autophagy by blocking 
autophagosome maturation. It is believed that inhibition 
of mTOR induces autophagosome formation, while 
inhibition of Vps34 blocks autophagosome-lysosome 
fusion, resulting in decreased autophagic flux, and 
accumulations of non-degraded autophagosomes. This 
finding differs from previous observations using PI-103, 
which suggest the drug increases autophagy activity [28]. 
While this earlier work focused largely on the levels of 
LC3 and p62, our approach encompasses additional 
factors such as alternative autophagy substrates, lysosome 
status and autolysosome fusion. Although we consistently 
found PI-103 to cause impaired p62 degradation across 
all the cell types tested in this study, it is interesting to 
note that Fan et al. [28] report a decrease in p62 with PI-
103 treatment in glioma cell lines (although it is unknown 
whether PI-103 alters p62 mRNA levels in the settings). 
Therefore, it is possible that the effect of PI-103 and DKI 
on autophagy flux may be influenced in part by cell type. 
Further investigation may be warranted to elucidate the 
effect of DKI on cell types of interest. 
Although Vps34 is critical for generating PI(3)P 
in the process of autophagosome formation [7], our data 
show increased levels of LC3-positive vesicles/LC3-II 
levels in Vps34 knockdown cells. These data are wholly 
in agreement with recent reports with Vps34 knockout 
[55] and a highly selective Vps34 inhibitor [56] on a 
number of grounds. First, LC3 lipidation is independent 
of Vps34 activity [55] (see also in Figure 5); second, 
LC3 vesicle accumulation may be partially caused 
by LC3 protein aggregation in Vps34-defective cells 
[55]; third, Vps34 complex II is required for endocytic 
sorting (including sorting of hydrolytic enzymes to 
the lysosome/vacuole and early steps in the endocytic 
pathway), endosome maturation and autophagosome 
maturation [50-53] (defects in autophagosome maturation 
cause autophagosome accumulation); finally, despite the 
importance of Vps34 in autophagosome formation, it is 
dispensable for the process. A number of studies have 
shown instances of non-canonical Vps34 independent 
autophagy in mammalian cells [57, 58]. Recent estimates 
have suggested Vps34 is accountable for ~65% of PI(3)
P production [67], with the remainder attributed to other 
sources such as the less well characterized Class II PI(3)
K [68]. In addition, Rubinsztein and colleagues have 
reported that PI(5)P can be used for autophagosome 
formation, serving a compensatory role in the absence of 
PI(3)P [59]. Indeed, Juhasz et al. [69] previously showed 
accumulation of autophagosomes in ESCRT/Vps34 double 
mutants, which indicates that loss of Vps34 does not 
completely prevent autophagosome formation, suggesting 
PI(3)P may not be absolutely essential for this process. On 
the other hand, the lack of autophagosome accumulation 
in Vps34 single mutants indicate that ESCRT complexes 
are partially functional in the absence of Vps34 [69]. 
Therefore, DKI treatment appears to perturb Vps34 
activity and autophagosome maturation, thereby leading 
to suppression of autophagy flux, which contributes to cell 
death. 
Previously DKI-induced cell death was suggested 
to be apoptosis-dependent [28, 60]. However, it was 
unclear if inhibition of apoptosis blocks DKI-induced cell 
death. We observed PI-103 caused cell death even under 
conditions of apoptosis and necroptosis inhibition. The 
discrepancy may stem from the fact that previous research 
concluded apoptosis largely from increases in apoptosis 
marker expression, or different experimental settings 
such as cell types. Our approach, utilizing both chemical 
and genetic repressors of these cell death mechanisms, 
provides a robust analysis on this front. It is worth noting 
that we do not exclude the association of apoptosis (or 
necroptosis) with DKI treatment, but these pathways do 
not appear to be major determinants for DKI-induced cell 
death in our conditions. Although our data at current are 
largely speculative on this front, we believe that autophagy 
inhibition by PI-103 contributes to its induced cell death. 
Investigating this possibility may prove interesting ground 
for future research.
The PI-3K/mTOR dual inhibitors hold a promise 
for treating cancers [24, 25, 28]. Both PI-103 and 
NVP-BEZ-235 have been trialed in various tumours, 
and additional inhibitors continue to be developed and 
investigated [30, 31]. Our finding, which clarifies that the 
dual inhibitors also inhibit autophagy, is important since 
autophagy is critical for cellular energy and nutrition 
homeostasis, as well as cell survival [70]. Elevated levels 
of autophagy in tumours are also associated with improved 
stress resistance and toxin removal, which can form a 
barrier to medical treatment [71]. To counter this response, 
a number of studies have coupled chemotherapy or 
radiotherapy with inhibition of autophagy flux, and shown 
enhanced toxicity to tumours [72, 73]. Interestingly, dual 
PI-3K/mTOR inhibitors have also proven to boost the 
efficacy of such therapies [26, 27]. Our results highlight 
a mechanism by which these synergistic effects are 
achieved. Given that the dual kinase inhibitors of PI-3K/
mTOR have been widely implicated in clinical treatment 





Rabbit polyclonal antibodies: anti-LC3 (1:10,000) 
(Novus Biologicals, NB100-2220); anti-phospho-70S6K 
(Thr389) (1:1,000) (Cell Signaling, 9205); anti-Akt 
(pan) (1:1,000) (Cell Signaling, 4691); anti-phospho-Akt 
(Ser473) (1:1,000) (Cell Signaling, 4060); anti-ULK1 
(pan) (1:1,000) (Cell Signaling, 8054); anti-phospho-
ULK1 (Ser757) (1:1,000) (Cell Signaling, 6888); anti-
phospho-4E-BP1 (Thr37/46) (1:1,000) (Cell Signaling, 
2855); anti-Atg12 (1:500) (Cell Signaling, 4180); anti-
RIP1 (1:1,000) (Cell Signaling, 3493); anti-caspase 3 
(1:1,000) (Cell Signaling, 9662); anti-Cleaved caspase 3 
(1:1,000) (Cell Signaling, 9661); anti-caspase 8 (1:1,000) 
(Cell Signaling, 9746); anti-caspase 9 (1:1,000) (Cell 
Signaling, 9504); anti-LAMP1 (1:1,000) (Cell Signaling, 
9091); anti-mTOR 7C10 (1:500) (Cell Signaling, 
2983); anti-PI3 Kinase Class III (Vps34) (1:500) (Cell 
Signaling, 3358); anti-actin (1:2,000) (Sigma, A2066). 
Goat polyclonal antibody: anti-cathepsin D (1:200) (Santa 
Cruz, sc-6486). Anti-mouse monoclonal antibodies: anti-
GAPDH (1:5,000) (Ambion, AM4300); anti-p62 (1:1,000) 
(BD, 610833); anti-tubulin (1:10,000) (Sigma, T9026). 
Bafilomycin A1 (Baf) (19-148) was purchased from 
Millipore. Chloroquine (CQ) (C6628), 3-methyladenine 
(3-MA) (M9281), rapamycin (Rap) (R0395), staurosporine 
(STS) (S5921), cycloheximide (C4859), artesunate (ART) 
(A3731) and necrostatin-1 (Nec) (N9037) were purchased 
from Sigma. zVAD-fmk (zVAD) (627610) was a product 
of Merck. PI-103 (528100) was from EMD4Biosciences, 
and NVP-BEZ-235 (10565) was purchased from Cayman 
Chemical. LY294002 (LY) (9901) was purchased from 
Cell Signaling Technology, and Human TNF-α was from 
Invitrogen (Sino Biological, 10602-HNAE-5). siRNAs 
were from Invitrogen (Ambion) or Dharmacon.
Cell culture
Bax/Bak WT and double-knockout (DKO) 
MEFs, used in our previous study [41], RT4-D6P2T 
(RT4) schwannoma cells [66], purchased from Sigma 
(93011415), and HeLa cells were cultured in DMEM 
(D6046) media with 10% fetal bovine serum (FBS) 
(12133C) (Sigma). 
siRNA transfection
Cells were split to 60-80% confluence and incubated 
in antibiotic-free DMEM containing 10% FBS. siRNAs 
were transfected with Lipofectamine 2000 (Invitrogen) 
as per the manufacturer’s instructions. siRNAs were 
used at a final concentration of 50nM. Non-targeting 
siRNA was the control siRNA. Cells were maintained 
in 10% FBS DMEM media without antibiotics for 24 
hours post transfection, and then incubated in DMEM 
with 10% FBS for further 24-48 hours after medium 
change. Human RIP1 siRNA (#J-004445-07) and 
caspase-8 siRNA (#J-003466-16) were obtained from 
Dharmacon. Human siRNA sequences: FRAP1 (mTOR): 
(Sense: 5’-GGGCAUGAAUCGGGAUGAU-3’) 
(Invitrogen); PIK3C3 (Vps34): (Sense: 
5’-GGGAAGAGAGAACAAAAGA-3’) 
(Invitrogen); caspase-3: (Sense: 
5’-UGGAUUAUCCUGAGAUGGG-3’) 
(Invitrogen); caspase-9: (5’-Sense: 
GGUUCUCAGACCGGAAACA-3’) (Invitrogen). 
Cell viability assay
1. ATP assays. Cell survival was determined with 
Cell Titer-Glo Luminescent Cell Viability Assay kit 
(Promega, G7571) to measure ATP levels according to the 
manufacturer’s instruction. Briefly, 100ul of Cell Titer-
Glo reagent was added to the culture medium. Cells were 
placed on a shaker for 5 min and then incubated at room 
temperature for 10 min. The SPECTRA Max M5 reader 
was used for Luminescent reading. 
2. MTT assays. MTT was purchased from 
Invitrogen. Briefly, 10ul of a 12mM MTT stock solution 
was added to culture medium and incubated at 37°C for 
4 hours. Medium was exchanged with 100ul DMSO, 
mixed by pipetting, and placed on a plate shaker for 
10 min. Absorbance was read at 562nm and a reference 
measurement at 650nm using the TECAN GENios 
V4.62-07/01 microplate reader (Tecan, Reading, UK) and 
XFLUOR4 Version V 4.51 software (Tecan).
Cell proliferation assay
Cell proliferation was measured using BrdU 
Cell Proliferation Assay kit (Cell Signaling, 6813) and 
performed following the manufacturer’s instructions. 
Absorbance was read at 450nm using the TECAN GENios 
V4.62-07/01 microplate reader (Tecan, Reading, UK) and 
XFLUOR4 Version V 4.51 software (Tecan).
Flow-cytometry cell death assays
Cells were trypsinised and washed twice with cold 
PBS, then resuspended in 1x binding buffer (10mM 
HEPES, pH 7.4; 140mM NaCl; 2.5mM CaCl2) at 1x106 
cells/ml. We transferred 100ul of cells to a FACS tube, 
added 5ul propidium iodide (Sigma) and incubated for 15 
min at room temperature. We added 200ul of 1xbinding 
buffer into each tube and analysed by flow cytometry.
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Immunocytochemistry
Cells were washed with PBS twice before fixation 
with 4% paraformaldehyde for 10 min. After a further 
three PBS washes, the fixed cells were permeabilised with 
0.5% Triton in PBS for 10 min. Cells were blocked in 
blocking buffer (1% BSA, 1% heat inactivated goat serum 
in PBS) for 30 min at room temperature, and incubated 
with primary antibodies overnight at 4°C. Cells were 
subjected to three 10 min PBS washes, incubated with 
secondary antibodies for 30 min, then followed by an 
additional three 10 min PBS washes. Slides were mounted 
with DAPI (3ug/ml). 
mRFP-GFP-LC3 assay
HeLa cells stably expressing mRFP-GFP-LC3 were 
treated with compounds at the indicated concentrations. 
After 24 hours, cells were fixed in 2% PFA for 5 min. 
Cellomics (Arrayscan VTI) was used to score green 
and red vesicles. Green vesicles are considered to be 
autophagosomes and red vesicles are considered to be 
both autophagosomes and autolysosomes. The number of 
autolysosomes was achieved by subtracting the number of 
green vesicles from that of the red vesicles.
Analysis of autophagosomes/vesicles
In experiments requiring a precise assessment of 
vesicle number, the number of vesicles per cell in GFP 
or RFP-positive cells was determined. Approximately 
100 cells per sample were counted for triplicate samples, 
as described previously [41] or otherwise methods are 
described in each figure legend. All coverslips were scored 
with the observer blinded to the identity of the slides. 
Acridine orange staining
Following drug treatment incubation, cells were 
stained with 2.5µg/ml acridine orange (Fisher) for 15 
min at 37°C and washed twice with PBS. Live cell 
imaging was performed on a Leica TCSSP8 with a 1.4nm 
63x objective. The argon laser at 488nm was used for 
excitation with emission collected simultaneously at both 
505-570nm and 615-754nm.
LysoSensor green staining
Following drug treatment, cells were stained with 
1uM LysoSensor Green DND-189 (Fisher) for 30 minutes 
at 37oC. The media was exchanged and then live cell 
imaging was performed by confocal microscopy using an 
excitation wavelength of 488nm. 
Subcellular fractionation
Cell fractionation was performed following Jahreiss 
et al [74]. Briefly, cells were harvested and pellets washed 
once in PBS, then resuspended in fractionation buffer 
(10mM HEPES pH7.9, 10mM KCl, 1.5mM MgCl2, 
0.1mM EGTA, 0.5mM DTT, 0.5mM PMSF and 10ug/
ml proteinase inhibitor). This mix was passed through a 
21-gauge needle 10 times and kept on ice for 45 min. After 
removing some of the lysate (total fraction), samples were 
centrifuged (30 min, 16,000 x g, 4°C). The supernatant 
(cytosolic fraction) was collected. The pellet (membrane 
fraction) was washed twice with fractionation buffer (7 
min, 16,000 x g, 4°C) before running with SDS-PAGE.
qRT-PCR analysis
RNA isolation was performed with TRIzol reagent 
as instructed (Invitrogen). For qPCR analysis, 1ug RNA 
was reverse transcribed (Applied Biosystems, Paisley, 
UK) using cycles of 25°C (10 min), 37°C (120 min) and 
85°C (5 min). cDNA templates were then used in qPCR 
with LightCycler 480 DNA SYBR Green I Master 
kit (Roche) in LightCycler 480 II system (Roche). 
All primers were from Sigma and used at 0.5uM. 
Actin was used as a control to normalize the data. 
Actin primers: 5′-ACTGGCATCGTGATGGACTC-3′ 
(forward) and 5′-TCAGGCAGCTCGTAGCTCTT-3′ 
(reverse); LC3-B primers: 
5′-ACGATACAAGGGTGAGAAGCA-3′ (forward) 
and 5′-GTCCGTTCACCAACAGGAAG-3′ (reverse); 
p62 primers: 5′-AGATGAGGAAGATCGCCTTG-3′ 
(forward) and 5′-GGCATCTGTAGGGACTGGAG-3′ 
(reverse); mTOR primers: 
5′-TAAGAAAACGGGGACCACAG-3′ (forward) and 
5′-TGAGAGAAGTCCCGACCAGT-3′ (reverse); Vps34 
primers: 5′-TCCTTGATGGTTGATGCAAA-3′ (forward) 
and 5′-CAGCAAAAAGAGCATGGACA-3′ (reverse). 
Quantification of autoradiographs
To quantify protein band density, the relevant 
specified bands were analysed using PhosphoImage 
software. The relative value was computed.
Statistics
T-test was used and P-values were determined by 
unconditional logistical regression analysis by using the 
general loglinear option of SPSS 9.1 software (SPSS, 
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